ABSTRACT
the likely recognition of the Y 4 and Y 5 subtypes. We were surprised to find that the visualization of these specific binding sites by receptor autoradiography clearly revealed the distinct distribution of specific 125 I-[Leu 31 ,Pro 34 ]hPYY (in presence of Y 1 and Y 5 blockers) and 125 I-hPP (in presence of Y 5 blocker) binding sites. Moreover, significant amounts of specific 125 IhPP binding were observed in the medial preoptic area, paraventricular nucleus of the hypothalamus, interpeduncular nucleus, and various brainstem nuclei, even after masking Y 4 and Y 5 receptors. Similar results were obtained using in presence of Y 2 and Y 5 blockers. These results suggest the possible existence of at least one additional subtype of NPY receptor sites in the rat brain, with enrichment seen in midbrain and brainstem areas involved in the regulation of food intake and cardiorespiratory parameters.
Neuropeptide Y (NPY) is a 36-amino acid residue polypeptide that shares high sequence homology with two other peptides, peptide YY (PYY) and the pancreatic polypeptides (PPs) (Tatemoto, 1982) . NPY and its related peptides have been implicated in several physiological functions, including regulation by the central nervous system of feeding, cardiorespiratory parameters, and anxiety-related behaviors (Vezzani et al., 1999; Kask et al., 2002; Berglund et al., 2003a; Kalra and Kalra, 2004) . The various effects of this peptide family are mediated by the activation of at least five receptor subtypes designated as Y 1 , Y 2 , Y 4 , Y 5 , and y 6 (Michel et al., 1998) . They have all been cloned and belong to the seven transmembrane G protein-coupled receptor type 1 superfamily (Michel et al., 1998; Dumont et al., 2004a) . They are expressed as functional receptors in various rat and human tissues, except for the y 6 subtype, which is restricted to mouse and rabbit (Michel et al., 1998) .
Various studies reported on the discrete neuroanatomical distribution of NPY receptor subtypes. For example, using ,Pro 34 ]hPYY as radioligand in the presence of selective nonpeptide Y 1 receptor antagonists such as BIBP3226 and BIBO3304, we proposed that residual specific labeling had a ligand selectivity profile very similar to that of the Y 5 receptor subtype in the rat CNS (Dumont et al., 1998) . These results were confirmed using the Y 5 receptor antagonist CGP71683A (Dumont et al., 2000a) . However, under these assay conditions, the possible recognition of the Y 4 subtype could not be fully excluded because [Leu 31 , Pro 34 ]PYY is known to possess nanomolar affinity for this receptor (Gehlert et al., 1996) . It is interesting that, using purported Y 4 ligands such as 125 I-hPP, 125 I-rPP, and 125 I-labeled bovine PP, we were able to visualize a very discrete distribution of specific receptor sites with moderate to very high amounts seen in a few regions, including the medial preoptic area, paraventricular nucleus of the hypothalamus, and interpeduncular nucleus (Trinh et al., 1996; Gehlert et al., 1997) . Furthermore, quantitative receptor autoradiography has demonstrated that labeling seen with 125 I-rPP (a Y 4 ligand with low affinity for the Y 5 receptor) was not identical to that of specific 125 I-hPP. In some rat brain nuclei such as the interpeduncular nuclei, nucleus tractus solitarius, and area postrema, higher levels of specific 125 I-hPP binding sites were detected compared with specific 125 I-rPP binding (Trinh et al., 1996) (Gehlert et al., 1997) and 125 I-GR231118 (Dumont and Quirion, 2000; Schober et al., 2000) binding sites even if these two radioligands are known to possess high affinities for the Y 4 receptor subtype (Dumont et al., 2004a) . These results could be taken as evidence for the existence of yet another class of sites preferentially recognized by PPrelated molecules. Moreover and rather surprisingly, using a novel highly selective Y 5 radioligand, , NPY(19-23), Ala 31 , Aib 32 , Gln 34 ]hPP, we could not detect specific binding in the nucleus tractus solitarius (Dumont et al., 2004b) , contrasting with our previous reports on the distribution of the Y 5 -like receptor subtype in rat brain using Pro 34 ]hPYY under Y 1 masking conditions (Dumont et al., 1998 (Dumont et al., , 2000a (Dumont et al., 1998 (Dumont et al., , 2004b .
To clarify these apparent discrepancies, we investigated here the ligand selectivity profile and discrete distribution of specific 125 
Materials and Methods
Materials. Male Sprague-Dawley CD rats (200 -250 g), obtained from Charles River Canada (St-Constant, Québec, Canada), were kept on a 12-h light/dark cycle (light on at 7:00 AM) in temperatureand humidity-controlled rooms. Animals were fed with standard laboratory chow and had access to tap water ad libitum. Animal care was according to protocols and guidelines approved by McGill University and the Canadian Council of Animal Care.
Analogs and fragments of hPYY, porcine (p)NPY, and hPP were synthesized as described previously (Forest et al., 1990 using the chloramine T method as described previously (Dumont et al., 1998) , except that the column used for the high-performance liquid chromatography purification of iodinated peptides was the C18 Guard-Pak. The specific activity of radioligands was assumed to be of the theoretical value (2000 Ci/ mmol).
Membrane Preparations. Membranes were prepared as described previously (Dumont et al., 1998) . In brief, rats were killed by decapitation and their brains were rapidly removed and homogenized in a Krebs-Ringer phosphate (KRP) buffer, pH 7.4, composed of 120 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 5.5 mM dextrose, and 25 mM NaHCO 3 using a Brinkmann Polytron (at setting 6 for 15-20 s). Homogenates were centrifuged at 49,000 ϫ g for 20 min; supernatants were discarded; and pellets were washed, resuspended, and recentrifuged twice.
Receptor Binding Assays. All binding assays were initiated by adding 100 l of membrane preparations in a final volume of 500 l of KRP containing 0.1% (w/v) BSA, 0.05% (w/v) bacitracin, radioligand, and unlabeled peptide or competitor as needed. After a 2-h incubation, the binding reaction was terminated by rapid filtration through Whatman Schleicher and Schuell #32 glass filters (previously soaked in 1.0% polyethylenimine) using a cell harvester filtering apparatus (Brandel Inc., Gaithersburg, MD). Filters were rinsed three times with 3 ml of ice-cold KRP, and the radioactivity remaining on filters was quantified using a gamma counter with 85% efficiency (Canberra Industries, Meriden, CT).
Quantitative Receptor Autoradiography. Receptor autoradiography was performed as described in detail previously (Dumont et al., 1998) . In brief, rats were sacrificed by decapitation, and their brains were rapidly removed from the skull, frozen in 2-methylbutane at Ϫ40°C for 15 s, and then kept at Ϫ80°C until needed. Sections (20 m) were obtained using a cryomicrotome at Ϫ17°C, mounted on gelatin-chrome-alum-coated slides, dried overnight in a desiccator at 4°C, and then kept at Ϫ80°C until use.
On the days of the experiments, adjacent coronal sections were preincubated for 60 min at room temperature in a KRP buffer at pH 7.4 and then incubated in a fresh preparation of KRP buffer containing 0.1% BSA, 0.05% bacitracin, 50 pM 125 I-hPP, 125 ILeu 31 ,Pro 34 ]hPYY, or in the presence and absence of 100 nM BIBO3304 (Y 1 blocker), 1000 nM BIIE0246 (Y 2 blocker), 10 nM GR231118 (Y 4 blocker), and various Y 5 receptor antagonists, such as JCF109, CGP71683A, CP732925, CP760542, and CP781214 (1000 nM). After a 2-h incubation, sections were washed four times, 1 min each in ice-cold KRP buffer, and then dipped in deionized water to remove salts and rapidly dried. Nonspecific binding was determined using 100 nM hPP, 1 M [Leu 31 ,Pro 34 ]hPYY, or 1 M hPYY(3-36). Incubated sections were apposed against Kodak BiomaxMR films (Eastman Kodak, Rochester, NY) for 7 to 14 days alongside radioactive standards. Films were developed and quantified as described in detail previously (Dumont et al., 1998) .
All binding experiments were repeated three to six times (each in triplicate), and results (mean Ϯ S.E.M.) are expressed as percentage of specific binding. K i values (concentration of unlabeled competitor required to compete for 50% of specific bound radioligand) for the various competitors were calculated using GraphPad Prism (GraphPad Software Inc., San Diego, CA) for a one-or two-site model.
Results
Previous studies have clearly demonstrated that 125 (Dumont et al., 2000c (Dumont et al., , 2004a recognized a heterogeneous population of receptor binding sites in the mammalian brains. All three radioligands bind to the Y 5 receptor subtype, although with different affinities (Michel et al., 1998; Dumont et al., 2004a (Cabrele et al., 2001) ; and nonpeptide Y 5 antagonists, such as CGP71683A (Criscione et al., 1998) , JCF109 (Feletou et al., 1999) , CP732925 (Elliott et al., 2003) , and CP760542 and CP781214 (Yannielli et al., 2004) . As shown in Fig. 1 125 I-hPP binding with nanomolar affinities (Fig. 2) . It is interesting that GR231118 and rPP possessed biphasic competition binding profiles (Fig. 2) . Specific 125 I-hPP binding also was competed by selective Y 5 agonists and antagonists. However, competition binding curves revealed that significant amounts of specific 125 I-hPP binding was not sensitive to Y 5 agonists and antagonists (Fig. 2) (Fig. 1) .
Competition binding curves were analyzed in detail, and data were fitted to one-or two-site models. As shown in Table 2) . Curve-fitting analysis revealed that rPP and GR231118 recognized at least two populations of sites, high-(K H of 0.3 to 0.6 nM) and low (K L of 115 nM)-affinity sites ( (Fig. 4) . Similar levels of inhibition was observed in these brain structures using any of the Y 5 competitors studied here, namely, CGP71683A, JCF109, CP732925, CP760542, CP781214, and [hPP(1-17),Ala 31 ,Aib 32 ]hNPY (Fig. 4) . Because competition curves of various agonists and antagonists revealed that 125 I-hPP recognized at least two population of sites, we also investigated the discrete distribution of specific 125 I-hPP binding in the presence of 1 or 1000 nM CP732925. As shown in Fig. 5 , significant amounts of specific 125 I-hPP binding were insensitive to the Y 5 antagonist in the medial preoptic area, paraventricular nucleus of the hypothalamus, interpeduncular nucleus, vestibular nucleus, nucleus tractus solitarius, and area postrema.
On the basis of current knowledge, specific binding visualized using 125 (Fig. 3) , whereas only very low levels of specific 125 I-hPP/Y 5 -insensitive sites were found in this structure (Fig. 5) (Fig.  3) , a much stronger signal was visualized using 125 I-hPP in the presence of a Y 5 blocker (Fig. 5) . In few other brain structures such as the nucleus tractus solitarius and area postrema, similar levels of specific 125 (Figs. 3 and 5) . To investigate this issue further, we evaluated specific 125 I-hPP binding in the presence of 10 nM GR231118, a concentration known to fully mask putative Y 4 receptor binding sites (Fig. 2) as well as residual specific 125 I-hPP binding in the presence of 10 nM GR231118 and 1000 nM CP732925 (to mask both Y 4 and Y 5 sites). As shown in Fig. 6 , significant amounts of specific 125 I-hPP binding were visualized in the interpeduncular nuclei, nucleus tractus solitarius, and area postrema, even in the presence of 10 nM GR231118 and 1000 nM CP732925. These unexpected data prompted us to investigate in detail residual specific 125 I-hPP binding in the presence of 10 nM GR231118 and different Y 5 blockers, including CGP71683A, JCF109, CP732925, CP760542, CP781214, [hPP(1-17), Ala 31 ,Aib 32 ]hNPY, and PYY. Quantitative receptor autoradiography revealed that all Y 5 molecules (agonists and antagonists) studied here were able to compete for similar amounts of specific sites labeled by 125 I-hPP (Fig. 7) . Most interestingly, high amounts of specific 125 I-hPP binding insensitive to both GR231118 and various Y 5 analogs were detected in the interpeduncular nucleus, nucleus tractus solitarius, area postrema and dorsal motor nucleus of the vagus, whereas moderate amounts were observed in the medial preoptic area, paraventricular nucleus of the hypothalamus, and vestibular nucleus (Fig. 7) . All other regions contained low to very low levels of those sites (Fig. 7) . Moreover, 1000 nM hPYY was not able to fully inhibit specific 125 I-hPP labeling in the presence of GR231118 (Fig. 7) , whereas residual specific 125 I-[Leu 31 ,Pro 34 ]hPYY binding in the presence of Y 1 and Y 5 blockers was fully competed by 1000 nM PYY (Fig. 4) .
We have previously reported that at the level of the area postrema, an area known to contain significant amounts of specific 125 I-hPYY(3-36)/Y 2 -insensitive binding sites (Dumont et al., 2000b) . As shown in Fig. 8 as radioligand, in the presence of Y 2 and Y 5 blockers. Therefore, these specific binding sites do not represent the cloned Y 1 , Y 2 , Y 4 , and Y 5 receptor subtypes. In fact, these data suggest that at least one additional class of NPY/PP receptors are expressed in the rat brain, especially in regions such as the interpeduncular nucleus, nucleus tractus solitarius, area postrema, and dorsal motor nucleus of the vagus.
NPY receptors have been characterized pharmacologically using various agonists and antagonists. The Y 1 subtype (Michel et al., 1998; Dumont et al., 2004a) . Selective Y 1 receptor antagonists have been developed, including BIBP3226 (Rudolf et al., 1994) , BIBO3304 (Wieland et al., 1998) , and GR231118 (Daniels et al., 1995) . The Y 2 subtype has high affinity for NPY, PYY and their C-terminal fragments (Michel et al., 1998; Dumont et al., 2004a) . Two nonpeptide Y 2 receptor antagonists have been characterized thus far, BIIE0246 (Doods et al., 1999) and JNJ-5207787 (Bonaventure et al., 2004) . The Y 4 subtype is characterized by its high affinity for PPs and GR231118 (as an agonist; Michel et al., 1998) . The Leu 31 Pro 34 -substituted analogs of NPY and PYY are also potent agonists on the Y 4 subtype (Gehlert et al., 1996) . This receptor subtype can be activated by PYY and NPY, but with much lower potencies than the PPs (Lundell et al., 1995 , and hPP display potent agonist activities, whereas NPY(13-36), PYY(13-36), rPP, and GR231118 are much less active (Michel et al., 1998; Dumont et al., 2004a (Cabrele et al., 2001 ). In addition, various nonpeptide Y 5 antagonists have been characterized including CGP71683A (Criscione et al., 1998) , JCF109 (Feletou et al., 1999) , CP732925 (Elliott et al., 2003) , and CP760542 and CP781214 (Yannielli et al., 2004 (Dumont et al., 1998) and the finding that BIBO3304 (Y 1 antagonist) and CGP71683A (Y 5 antagonist) were able to compete for 75 and 25% of specific ,Pro 34 ]hPYY binding, respectively (Dumont et al., 2000a) . However, it was not possible to exclude a possible contribution of the Y 4 subtype because Pro 34 ]PYY has rather high affinity for this subtype (Gehlert et al., 1997) . In the present study, we demonstrated that Pro 34 ]hPYY recognized at least three distinct classes of sites. As expected, the first two represent the Y 1 The discrete localization of the Y 4 subtype has previously been investigated using different radioligands including 125 IhPP and 125 I-rPP (Trinh et al., 1996) , 125 I-bovine PP (Gehlert et al., 1997) and 125 I-GR231118 (Dumont and Quirion, 2000; Schober et al., 2000) . Using these various probes, it was shown that specific 125 I-PP binding sites (the Y 4 subtype) are particularly enriched in the interpeduncular nuclei, nucleus tractus solitarius, and area postrema of the rat brain. In the present study, specific 125 AP, area postrema; CA1, subfield CA1 of hippocampus; CA2, subfield CA2 of hippocampus; CA3, subfield CA3 of hippocampus; CPu, caudate putamen (striatum); Deep, deep layers of the cortex; DG, dentate gyrus; DMH; dorsomedial hypothalamic nucleus; EPL, external plexiform layer of the olfactory bulb; Fr, frontal cortex; IP, interpeduncular nuclei; LH, lateral hypothalamic area; LS, lateral septal nucleus, LSD, lateral septal nucleus, dorsal part; Mid, mid layers of the cortex; MPA, medial preoptic area; n10, dorsal motor nucleus of the vagus, Par, parietal cortex, PVN, paraventricular nuclei of the hypothalamus; Sol, nucleus of the solitary tract; Sup, superficial layers of the cortex; Ve, vestibular nuclei.
receptors can form homodimers (Berglund et al., 2003b; Dinger et al., 2003) . The possible existence of Y 1 and Y 5 heterodimers has also been suggested (Schober et al., 2003) . However, there is no evidence that once NPY receptors form homo-or heterodimers, they display distinct pharmacological profiles compared with the native monomeric receptor (Schober et al., 2003) . Regarding the Y 3 subtype, the existence of this receptor was proposed on the basis of cardiovascular and cAMP responses induced only by NPY and its homologues; PYY and PP derivatives being inactive (Ny and Grundemar, 1997; Glaum et al., 1997) . Specific sites characterized in the present study clearly displayed high affinities for both PYY and PPs, excluding the Y 3 subtype as the one characterized here. It is noteworthy that elaborated phylogenic studies suggested the existence of additional NPY receptor subtypes, in fact up to eight to nine subtypes in total (Larhammar, 1996; Larhammar and Salaneck, 2004) .
At the functional level, the high expression of atypical specific [ 125 ] PYY(3-36) and 125 I-hPP binding sites in the area postrema is of interest because this region is devoid of a mature blood-brain barrier. Blood-borne PYY(3-36) (Batterham et al., 2002) and PPs (Batterham et al., 2003) were shown to be potent inhibitors of food intake. It was also suggested that the peripheral effects of PYY(3-36) on food intake were mediated by the Y 2 receptor subtype because peripheral administration of PYY(3-36) had no effect on this behavior in Y 2 knockout animals (Batterham et al., 2002) . However, this hypothesis cannot explain the effect obtained with i.v. injections of PPs because these peptides have no significant affinity for the Y 2 receptor subtype. The novel class of binding sites reported here represents an interesting alternative hypothesis, especially because the area postrema, nucleus tractus solitarius, and dorsal motor nucleus of the vagus are known to be involved in the regulation of food intake and cardiovascular parameters (Dumont et al., 2000c) In summary, competition binding experiments in rat brain membrane homogenates demonstrated that specific 125 
